Evonik Offers Green Tech for Sustainable Pharmaceutical Production

Article

Evonik has released an innovative green technology that can enable the large-scale synthesis of APIs in water.

Evonik, a German specialty chemicals company, has announced its latest offering, which is an innovative green technology that can enable the large-scale synthesis of APIs in water. The new offering was revealed in a June 29, 2021 press release.

The “Chemistry in Water” technology works by using surfactants that form microscopic spheres in water, called micelles. These micelles then take on the role of nanoreactors, which means that organic reactions can be performed in water rather than organic solvents.

As a result of the capability to replace organic solvents, this new technology has the potential to improve the environmental footprint of drug manufacturing. To achieve this novel approach, Evonik has collaborated with Bruce Lipshutz from the University of California, Santa Barbara.

“Improving the environmental footprint for the synthesis of [APIs] is critically important for the sustainability of drug manufacturing going forward,” said Stefan Randl, head of Research, Development, and Innovation for the Health Care business line of Evonik, in the press release. “It is a great pleasure to work with technology pioneer Professor Bruce Lipshutz and bring Chemistry in Water to commercial scale.”

“After many years developing aqueous micellar chemistry, it is immensely rewarding to see industry applying and further developing its potential,” added Lipshutz, in the press release. “I am confident that working closely with Evonik, as the first adopter for [contract development and manufacturing organization] purposes, will pave the way for wider applications to industrial projects and overall, more sustainable chemistry.”

Source: Evonik

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content